At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CADL Candel Therapeutics, Inc.
Closed Good Friday 04-17 16:00:00 EDT
4.57
+0.04
+0.88%
盘后4.55
-0.02-0.44%
19:50 EDT
| High4.78 | Low4.50 | Vol534.50K |
| Open4.61 | D1 Closing4.53 | Amplitude6.18% |
| Mkt Cap215.87M | Tradable Cap164.18M | Total Shares47.24M |
| T/O2.44M | T/O Rate1.49% | Tradable Shares35.93M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Promising Clinical Outcomes and Strategic Advances Boost Candel Therapeutics’ CAN-2409 Potential in Oncology
TIPRANKS · 04-11
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
GlobeNewswire · 04-01
Candel Therapeutics Reports Prolonged Survival In Mid-Stage Study For Pretreated Lung Cancer Patients
Benzinga · 03-27
Promising CAN-2409 Trial Results Drive Buy Rating for Candel Therapeutics
TIPRANKS · 03-27
Candel Therapeutics Reports Final Phase 2a Survival Data for Lung Cancer Treatment
MT Newswires Live · 03-26
Candel Therapeutics Reports Both Prolonged Median Overall Survival And Long Tail Of Survival In Phase 2A Clinical Trial Of CAN-2409 In Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Re
Reuters · 03-26
Candel Therapeutics Inc: Can-2409 Continued to Exhibit a Generally Favorable Safety and Tolerability Profile Throughout Extended Follow-up Period
THOMSON REUTERS · 03-26
Candel Therapeutics: Statistically Significant Improved Overall Survival in Non-Squamous Nsclc VS Squamous Nsclc After Can-2409 Experimental Treatment
THOMSON REUTERS · 03-26
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of Can-2409 in Advanced Non-Small Cell Lung Cancer (Nsclc) Patients Non-Responsive to Immune Checkpoint Inhibitor (Ici) Treatment
THOMSON REUTERS · 03-26
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
GlobeNewswire · 03-26
Candel Therapeutics Partners With IDEA Pharma for CAN-2409 Commercialization
MT Newswires Live · 03-20
Candel Therapeutics and Idea Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for Can-2409
THOMSON REUTERS · 03-20
Candel Therapeutics Inc - Partnership With Idea Pharma Expected to Run Through 2026
THOMSON REUTERS · 03-20
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
GlobeNewswire · 03-20
Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board
GlobeNewswire · 03-18
Candel Therapeutics Price Target Maintained With a $19.00/Share by HC Wainwright & Co.
Dow Jones · 03-14
Promising Clinical Results and Strong Potential of Candel Therapeutics’ CAN-2409 Justify Buy Rating
TIPRANKS · 03-14
BRIEF-Candel Therapeutics Q4 Net Income USD -14.073 Million
Reuters · 03-13
Candel Therapeutics Q4 Net Income USD -14.073 Million
THOMSON REUTERS · 03-13
Press Release: Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
Dow Jones · 03-13
Introduction
Company Name.
Candel Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App